リンパ球活性化遺伝子3タンパク質治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0367
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:107
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Lymphocyte Activation Gene 3 Protein – Pipeline Review, H2 2019
Summary

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens.

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 34 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 7, 1, 13, 5 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Cardiovascular, Gastrointestinal and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Diffuse Large B-Cell Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Triple-Negative Breast Cancer (TNBC), Cervical Cancer, Hepatocellular Carcinoma, Lymphoma, Ovarian Cancer, Small-Cell Lung Cancer, Colon Carcinoma, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Mesothelioma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Renal Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancy, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Blood Cancer, Breast Cancer, Cardiovascular Disease, Chronic Inflammation, Chronic Lymphocytic Leukemia (CLL), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Merkel Cell Carcinoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Nasopharyngeal Cancer, Neuroendocrine Tumors, Peritoneal Cancer, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rheumatoid Arthritis, Soft Tissue Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Lymphocyte Activation Gene 3 Protein – Pipeline Review, H2 2019, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Overview
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Companies Involved in Therapeutics Development
Abeome Corp
Avacta Life Sciences Ltd
BJ Bioscience Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Crescendo Biologics Ltd
Eli Lilly and Co
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
GigaGen Inc
GlaxoSmithKline Plc
I-Mab Biopharma Co Ltd
ILGEN Inc
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
Leads Biolabs Inc
Leidos Health
Lipid Genomics Inc
MacroGenics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Shanghai Henlius Biotech Inc
Stcube Inc
Sutro Biopharma Inc
Symphogen A/S
Xencor Inc
Y-Biologics
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Drug Profiles
(nivolumab + relatlimab) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-0003 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-021 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Dormant Products
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abeome Corp, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by BJ Bioscience Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Crescendo Biologics Ltd, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by F-star Biotechnology Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Fountain Biopharma Inc, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by ILGEN Inc, H2 2019
Pipeline by Immutep Ltd, H2 2019
Pipeline by Incyte Corp, H2 2019
Pipeline by Innovent Biologics Inc, H2 2019
Pipeline by Leads Biolabs Inc, H2 2019
Pipeline by Leidos Health, H2 2019
Pipeline by Lipid Genomics Inc, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Stcube Inc, H2 2019
Pipeline by Sutro Biopharma Inc, H2 2019
Pipeline by Symphogen A/S, H2 2019
Pipeline by Xencor Inc, H2 2019
Pipeline by Y-Biologics, H2 2019
Dormant Projects, H2 2019

【掲載企業】

Abeome Corp
Avacta Life Sciences Ltd
BJ Bioscience Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Crescendo Biologics Ltd
Eli Lilly and Co
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
GigaGen Inc
GlaxoSmithKline Plc
I-Mab Biopharma Co Ltd
ILGEN Inc
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
Leads Biolabs Inc
Leidos Health
Lipid Genomics Inc
MacroGenics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Shanghai Henlius Biotech Inc
Stcube Inc
Sutro Biopharma Inc
Symphogen A/S
Xencor Inc
Y-Biologics

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[リンパ球活性化遺伝子3タンパク質治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆